Gefitinib (Iressa, ZD1839) is an orally active EGFR-tyrosine kinase inhibitor (TKI) that blocks signal transduction pathways implicated in proliferation and survival of cancer cells (Baselga and Averbuch, 2000). The gene discussed is EGFR; the disease is cancer.